Company intelligence / Profile preview
Madera Therapeutics
Cary, North Carolina, United Statesmaderat.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Madera Therapeutics is developing small molecule cancer therapeutics that work by activating the mitochondrial protease ClpP. Their agents have demonstrated in vitro and in vivo efficacy, particularly against drug-resistant cancer cells and patient-derived tissue samples. The technology represents a new mechanism of action for oncology therapeutics but has not yet entered clinical trials.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
NIH/NCIAcademic collaborators
Beyond the preview
Go deeper on Madera Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Madera Therapeutics.